Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2013

01-03-2013 | Original article

Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms

Authors: Lixin Zhang, Anda Vlad, Christine Milcarek, Olivera J. Finn

Published in: Cancer Immunology, Immunotherapy | Issue 3/2013

Login to get access

Abstract

MUC1 is a transmembrane mucin with important functions in normal and transformed cells, carried out by the extracellular domain or the cytoplasmic tail. A characteristic feature of the MUC1 extracellular domain is the variable number of tandem repeats (VNTR) region. Alternative splicing may regulate MUC1 expression and possibly function. We developed an RT-PCR method for efficient isolation of MUC1 mRNA isoforms that allowed us to evaluate the extent of alternative splicing of MUC1 and elucidate some of the rules that govern this process. We cloned and analyzed 21, 24, and 36 isoforms from human tumor cell lines HeLa, MCF7, and Jurkat, respectively, and 16 from normal activated human T cells. Among the 78 MUC1 isoforms we isolated, 76 are new and different cells showed varied MUC1 expression patterns. The VNTR region of exon 2 was recognized as an intron with a fixed 5′ splice site but variable 3′ splice sites. We also report that the 3506 A/G SNP in exon 2 can regulate 3′ splice sites selection in intron 1 and produce different MUC1 short isoform proteins. Furthermore, the SNP A to G mutation was also observed in vivo, during de novo tumor formation in MUC1+/−KrasG12D/+PtenloxP/loxP mice. No specific functions have been associated with previously reported short isoforms. We now report that one new G SNP-associated isoform MUC1/Y-LSP, but not the A SNP-associated isoform MUC1/Y, inhibits tumor growth in immunocompetent but not immunocompromised mice.
Appendix
Available only for authorised users
Literature
2.
go back to reference Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302(5653):2141–2144PubMedCrossRef Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302(5653):2141–2144PubMedCrossRef
3.
go back to reference Xing Y, Lee C (2006) Alternative splicing and RNA selection pressure–evolutionary consequences for eukaryotic genomes. Nat Rev Genet 7(7):499–509PubMedCrossRef Xing Y, Lee C (2006) Alternative splicing and RNA selection pressure–evolutionary consequences for eukaryotic genomes. Nat Rev Genet 7(7):499–509PubMedCrossRef
4.
5.
go back to reference Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40(12):1413–1415PubMedCrossRef Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40(12):1413–1415PubMedCrossRef
6.
go back to reference Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456(7221):470–476PubMedCrossRef Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456(7221):470–476PubMedCrossRef
7.
go back to reference Nilsen TW, Graveley BR (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature 463(7280):457–463PubMedCrossRef Nilsen TW, Graveley BR (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature 463(7280):457–463PubMedCrossRef
8.
go back to reference Stamm S (2002) Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 11(20):2409–2416PubMedCrossRef Stamm S (2002) Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 11(20):2409–2416PubMedCrossRef
9.
10.
go back to reference Garcia-Blanco MA, Baraniak AP, Lasda EL (2004) Alternative splicing in disease and therapy. Nat Biotechnol 22(5):535–546PubMedCrossRef Garcia-Blanco MA, Baraniak AP, Lasda EL (2004) Alternative splicing in disease and therapy. Nat Biotechnol 22(5):535–546PubMedCrossRef
11.
go back to reference Pagani F, Baralle FE (2004) Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 5(5):389–396PubMedCrossRef Pagani F, Baralle FE (2004) Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 5(5):389–396PubMedCrossRef
12.
13.
go back to reference Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM (2007) Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 8(4):349–357PubMedCrossRef Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM (2007) Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 8(4):349–357PubMedCrossRef
14.
go back to reference Wang GS, Cooper TA (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8(10):749–761PubMedCrossRef Wang GS, Cooper TA (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8(10):749–761PubMedCrossRef
15.
go back to reference Kim E, Goren A, Ast G (2008) Insights into the connection between cancer and alternative splicing. Trends Genet 24(1):7–10PubMedCrossRef Kim E, Goren A, Ast G (2008) Insights into the connection between cancer and alternative splicing. Trends Genet 24(1):7–10PubMedCrossRef
16.
go back to reference Krawczak M, Reiss J, Cooper DN (1992) The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 90(1–2):41–54PubMed Krawczak M, Reiss J, Cooper DN (1992) The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 90(1–2):41–54PubMed
17.
go back to reference Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R (2005) Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579(9):1900–1903PubMedCrossRef Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R (2005) Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579(9):1900–1903PubMedCrossRef
18.
go back to reference Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, Lucier JF, Thibault P, Rancourt C, Tremblay K, Prinos P, Chabot B, Elela SA (2009) Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 16(6):670–676PubMedCrossRef Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, Lucier JF, Thibault P, Rancourt C, Tremblay K, Prinos P, Chabot B, Elela SA (2009) Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 16(6):670–676PubMedCrossRef
19.
go back to reference Li HR, Wang-Rodriguez J, Nair TM, Yeakley JM, Kwon YS, Bibikova M, Zheng C, Zhou L, Zhang K, Downs T, Fu XD, Fan JB (2006) Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res 66(8):4079–4088PubMedCrossRef Li HR, Wang-Rodriguez J, Nair TM, Yeakley JM, Kwon YS, Bibikova M, Zheng C, Zhou L, Zhang K, Downs T, Fu XD, Fan JB (2006) Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res 66(8):4079–4088PubMedCrossRef
20.
go back to reference Zhang M, Gish W (2006) Improved spliced alignment from an information theoretic approach. Bioinformatics 22(1):13–20PubMedCrossRef Zhang M, Gish W (2006) Improved spliced alignment from an information theoretic approach. Bioinformatics 22(1):13–20PubMedCrossRef
21.
go back to reference Theodoropoulos G, Carraway KL (2007) Molecular signaling in the regulation of mucins. J Cell Biochem 102(5):1103–1116PubMedCrossRef Theodoropoulos G, Carraway KL (2007) Molecular signaling in the regulation of mucins. J Cell Biochem 102(5):1103–1116PubMedCrossRef
22.
go back to reference Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293PubMedCrossRef Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249–293PubMedCrossRef
23.
go back to reference Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J (1992) Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 267(9):6171–6177PubMed Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J (1992) Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 267(9):6171–6177PubMed
24.
go back to reference Fontenot JD, Finn OJ, Dales N, Andrews PC, Montelaro RC (1993) Synthesis of large multideterminant peptide immunogens using a poly-proline beta-turn helix motif. Pept Res 6(6):330–336PubMed Fontenot JD, Finn OJ, Dales N, Andrews PC, Montelaro RC (1993) Synthesis of large multideterminant peptide immunogens using a poly-proline beta-turn helix motif. Pept Res 6(6):330–336PubMed
25.
go back to reference Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ (1993) Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res 53(22):5386–5394PubMed Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ (1993) Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res 53(22):5386–5394PubMed
26.
go back to reference Fukuda M (2002) Roles of mucin-type O-glycans in cell adhesion. Biochim Biophys Acta 1573(3):394–405PubMedCrossRef Fukuda M (2002) Roles of mucin-type O-glycans in cell adhesion. Biochim Biophys Acta 1573(3):394–405PubMedCrossRef
27.
go back to reference Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV (1992) Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 17(9):359–363PubMedCrossRef Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV (1992) Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 17(9):359–363PubMedCrossRef
28.
go back to reference Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG, Finn OJ (2005) Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 175(3):1628–1635PubMed Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG, Finn OJ (2005) Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 175(3):1628–1635PubMed
29.
30.
go back to reference Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86(18):7159–7163PubMedCrossRef Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86(18):7159–7163PubMedCrossRef
31.
go back to reference Saeland E, van Vliet SJ, Backstrom M, van den Berg VC, Geijtenbeek TB, Meijer GA, van Kooyk Y (2007) The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother 56(8):1225–1236PubMedCrossRef Saeland E, van Vliet SJ, Backstrom M, van den Berg VC, Geijtenbeek TB, Meijer GA, van Kooyk Y (2007) The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother 56(8):1225–1236PubMedCrossRef
32.
go back to reference Ren J, Raina D, Chen W, Li G, Huang L, Kufe D (2006) MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 4(11):873–883PubMedCrossRef Ren J, Raina D, Chen W, Li G, Huang L, Kufe D (2006) MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 4(11):873–883PubMedCrossRef
33.
go back to reference Mahanta S, Fessler SP, Park J, Bamdad C (2008) A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One 3(4):e2054PubMedCrossRef Mahanta S, Fessler SP, Park J, Bamdad C (2008) A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One 3(4):e2054PubMedCrossRef
34.
go back to reference Ren J, Li Y, Kufe D (2002) Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 277(20):17616–17622PubMedCrossRef Ren J, Li Y, Kufe D (2002) Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 277(20):17616–17622PubMedCrossRef
35.
go back to reference Wei X, Xu H, Kufe D (2005) Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7(2):167–178PubMedCrossRef Wei X, Xu H, Kufe D (2005) Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7(2):167–178PubMedCrossRef
36.
go back to reference Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D (2007) The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 27(6):992–1004PubMedCrossRef Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D (2007) The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 27(6):992–1004PubMedCrossRef
37.
go back to reference Levitin F, Baruch A, Weiss M, Stiegman K, Hartmann ML, Yoeli-Lerner M, Ziv R, Zrihan-Licht S, Shina S, Gat A, Lifschitz B, Simha M, Stadler Y, Cholostoy A, Gil B, Greaves D, Keydar I, Zaretsky J, Smorodinsky N, Wreschner DH (2005) A novel protein derived from the MUC1 gene by alternative splicing and frameshifting. J Biol Chem 280(11):10655–10663PubMedCrossRef Levitin F, Baruch A, Weiss M, Stiegman K, Hartmann ML, Yoeli-Lerner M, Ziv R, Zrihan-Licht S, Shina S, Gat A, Lifschitz B, Simha M, Stadler Y, Cholostoy A, Gil B, Greaves D, Keydar I, Zaretsky J, Smorodinsky N, Wreschner DH (2005) A novel protein derived from the MUC1 gene by alternative splicing and frameshifting. J Biol Chem 280(11):10655–10663PubMedCrossRef
38.
go back to reference Baruch A, Hartmann M, Zrihan-Licht S, Greenstein S, Burstein M, Keydar I, Weiss M, Smorodinsky N, Wreschner DH (1997) Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer 71(5):741–749PubMedCrossRef Baruch A, Hartmann M, Zrihan-Licht S, Greenstein S, Burstein M, Keydar I, Weiss M, Smorodinsky N, Wreschner DH (1997) Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer 71(5):741–749PubMedCrossRef
39.
go back to reference Rubinstein DB, Karmely M, Ziv R, Benhar I, Leitner O, Baron S, Katz BZ, Wreschner DH (2006) MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res 66(23):11247–11253PubMedCrossRef Rubinstein DB, Karmely M, Ziv R, Benhar I, Leitner O, Baron S, Katz BZ, Wreschner DH (2006) MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells. Cancer Res 66(23):11247–11253PubMedCrossRef
40.
go back to reference Oosterkamp HM, Scheiner L, Stefanova MC, Lloyd KO, Finstad CL (1997) Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). Int J Cancer 72(1):87–94PubMedCrossRef Oosterkamp HM, Scheiner L, Stefanova MC, Lloyd KO, Finstad CL (1997) Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). Int J Cancer 72(1):87–94PubMedCrossRef
41.
go back to reference Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58(2):315–321PubMed Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58(2):315–321PubMed
42.
go back to reference Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70PubMedCrossRef Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70PubMedCrossRef
43.
go back to reference Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM (2011) Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 60(7):975–984PubMedCrossRef Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM (2011) Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 60(7):975–984PubMedCrossRef
44.
go back to reference Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H (2002) Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32(2):148–149PubMedCrossRef Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H (2002) Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32(2):148–149PubMedCrossRef
45.
go back to reference Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM (2009) A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Disease Models Mech 2(11–12):593–603CrossRef Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM (2009) A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Disease Models Mech 2(11–12):593–603CrossRef
46.
go back to reference Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4):285–298PubMedCrossRef Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4):285–298PubMedCrossRef
47.
go back to reference Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, Finn OJ (2003) Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology 108(1):32–41PubMedCrossRef Correa I, Plunkett T, Vlad A, Mungul A, Candelora-Kettel J, Burchell JM, Taylor-Papadimitriou J, Finn OJ (2003) Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology 108(1):32–41PubMedCrossRef
48.
go back to reference Agrawal B, Krantz MJ, Parker J, Longenecker BM (1998) Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res 58(18):4079–4081PubMed Agrawal B, Krantz MJ, Parker J, Longenecker BM (1998) Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res 58(18):4079–4081PubMed
49.
go back to reference Fattorossi A, Battaglia A, Malinconico P, Stoler A, Andreocci L, Parente D, Coscarella A, Maggiano N, Perillo A, Pierelli L, Scambia G (2002) Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells. Exp Cell Res 280(1):107–118PubMedCrossRef Fattorossi A, Battaglia A, Malinconico P, Stoler A, Andreocci L, Parente D, Coscarella A, Maggiano N, Perillo A, Pierelli L, Scambia G (2002) Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells. Exp Cell Res 280(1):107–118PubMedCrossRef
50.
go back to reference Ligtenberg MJ, Gennissen AM, Vos HL, Hilkens J (1991) A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA. Nucleic Acids Res 19(2):297–301PubMedCrossRef Ligtenberg MJ, Gennissen AM, Vos HL, Hilkens J (1991) A single nucleotide polymorphism in an exon dictates allele dependent differential splicing of episialin mRNA. Nucleic Acids Res 19(2):297–301PubMedCrossRef
51.
go back to reference Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM (2008) Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer 99(6):978–985PubMedCrossRef Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM (2008) Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer 99(6):978–985PubMedCrossRef
52.
go back to reference Roberts GC, Smith CW (2002) Alternative splicing: combinatorial output from the genome. Curr Opin Chem Biol 6(3):375–383PubMedCrossRef Roberts GC, Smith CW (2002) Alternative splicing: combinatorial output from the genome. Curr Opin Chem Biol 6(3):375–383PubMedCrossRef
53.
go back to reference Zhu J, Shendure J, Mitra RD, Church GM (2003) Single molecule profiling of alternative pre-mRNA splicing. Science 301(5634):836–838PubMedCrossRef Zhu J, Shendure J, Mitra RD, Church GM (2003) Single molecule profiling of alternative pre-mRNA splicing. Science 301(5634):836–838PubMedCrossRef
54.
go back to reference Zhang XH, Chasin LA (2004) Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 18(11):1241–1250PubMedCrossRef Zhang XH, Chasin LA (2004) Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 18(11):1241–1250PubMedCrossRef
55.
go back to reference McCarthy EM, Phillips JA 3rd (1998) Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA. Hum Mol Genet 7(9):1491–1496PubMedCrossRef McCarthy EM, Phillips JA 3rd (1998) Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA. Hum Mol Genet 7(9):1491–1496PubMedCrossRef
56.
go back to reference Ule J, Stefani G, Mele A, Ruggiu M, Wang X, Taneri B, Gaasterland T, Blencowe BJ, Darnell RB (2006) An RNA map predicting Nova-dependent splicing regulation. Nature 444(7119):580–586PubMedCrossRef Ule J, Stefani G, Mele A, Ruggiu M, Wang X, Taneri B, Gaasterland T, Blencowe BJ, Darnell RB (2006) An RNA map predicting Nova-dependent splicing regulation. Nature 444(7119):580–586PubMedCrossRef
57.
go back to reference Lian Y, Garner HR (2005) Evidence for the regulation of alternative splicing via complementary DNA sequence repeats. Bioinformatics 21(8):1358–1364PubMedCrossRef Lian Y, Garner HR (2005) Evidence for the regulation of alternative splicing via complementary DNA sequence repeats. Bioinformatics 21(8):1358–1364PubMedCrossRef
58.
go back to reference Eperon LP, Estibeiro JP, Eperon IC (1986) The role of nucleotide sequences in splice site selection in eukaryotic pre-messenger RNA. Nature 324(6094):280–282PubMedCrossRef Eperon LP, Estibeiro JP, Eperon IC (1986) The role of nucleotide sequences in splice site selection in eukaryotic pre-messenger RNA. Nature 324(6094):280–282PubMedCrossRef
59.
go back to reference Thompson-Jager S, Domdey H (1987) Yeast pre-mRNA splicing requires a minimum distance between the 5′ splice site and the internal branch acceptor site. Mol Cell Biol 7(11):4010–4016PubMed Thompson-Jager S, Domdey H (1987) Yeast pre-mRNA splicing requires a minimum distance between the 5′ splice site and the internal branch acceptor site. Mol Cell Biol 7(11):4010–4016PubMed
60.
go back to reference Carson DD (2008) The cytoplasmic tail of MUC1: a very busy place. Sci Signal 1(27):35CrossRef Carson DD (2008) The cytoplasmic tail of MUC1: a very busy place. Sci Signal 1(27):35CrossRef
61.
go back to reference Jia Y, Persson C, Hou L, Zheng Z, Yeager M, Lissowska J, Chanock SJ, Chow WH, Ye W (2010) A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer. Cancer Causes Control 21(2):313–321PubMedCrossRef Jia Y, Persson C, Hou L, Zheng Z, Yeager M, Lissowska J, Chanock SJ, Chow WH, Ye W (2010) A comprehensive analysis of common genetic variation in MUC1, MUC5AC, MUC6 genes and risk of stomach cancer. Cancer Causes Control 21(2):313–321PubMedCrossRef
62.
go back to reference Xu Q, Yuan Y, Sun LP, Gong YH, Xu Y, Yu XW, Dong NN, Lin GD, Smith PN, Li RW (2009) Risk of gastric cancer is associated with the MUC1 568 A/G polymorphism. Int J Oncol 35(6):1313–1320PubMed Xu Q, Yuan Y, Sun LP, Gong YH, Xu Y, Yu XW, Dong NN, Lin GD, Smith PN, Li RW (2009) Risk of gastric cancer is associated with the MUC1 568 A/G polymorphism. Int J Oncol 35(6):1313–1320PubMed
63.
go back to reference David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24(21):2343–2364PubMedCrossRef David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24(21):2343–2364PubMedCrossRef
Metadata
Title
Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms
Authors
Lixin Zhang
Anda Vlad
Christine Milcarek
Olivera J. Finn
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1325-2

Other articles of this Issue 3/2013

Cancer Immunology, Immunotherapy 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine